| scholarly article | Q13442814 |
| P356 | DOI | 10.1377/HLTHAFF.25.5.1218 |
| P698 | PubMed publication ID | 16966717 |
| P2093 | author name string | Steven D Pearson | |
| Sean R Tunis | |||
| P433 | issue | 5 | |
| P304 | page(s) | 1218-1230 | |
| P577 | publication date | 2006-09-01 | |
| P1433 | published in | Health Affairs | Q260110 |
| P1476 | title | Coverage options for promising technologies: Medicare's 'coverage with evidence development' | |
| P478 | volume | 25 |
| Q50107692 | "There is always a better way": Managing uncertainty in decision making about new cancer drugs in Canada |
| Q37661666 | A common policy framework for evidence generation on promising health technologies |
| Q35854145 | A formal risk-benefit framework for genomic tests: Facilitating the appropriate translation of genomics into clinical practice |
| Q82349672 | A policy approach to the development of molecular diagnostic tests |
| Q87372252 | Accelerated access to innovative medicines for patients in need |
| Q39908682 | Access with evidence development in the UK: past experience, current initiatives and future potential. |
| Q39908685 | Access with evidence development: the US experience |
| Q37984169 | Adaptive licensing: taking the next step in the evolution of drug approval |
| Q46638150 | Applying Value-Based Insurance Design To High-Cost Health Services |
| Q38188436 | Approaches to assessing the benefits and harms of medical devices for application in surgery |
| Q37118613 | Biopharmaceuticals: the economic equation |
| Q37912286 | Breaking up is hard to do: the economic impact of provisional funding contingent upon evidence development. |
| Q50227366 | Challenges for the new Cancer Drugs Fund |
| Q36326845 | Challenges in Australian policy processes for disinvestment from existing, ineffective health care practices |
| Q28756810 | Clearing up the hazy road from bench to bedside: a framework for integrating the fourth hurdle into translational medicine |
| Q34141791 | Comparative Effectiveness Research: From Clinical Information To Economic Incentives |
| Q33896568 | Comparative effectiveness research in Ontario, Canada: producing relevant and timely information for health care decision makers |
| Q36417749 | Cost, coverage, and comparative effectiveness research: the critical issues for oncology |
| Q39911359 | Coverage with Evidence Development: applications and issues |
| Q81443710 | Coverage with evidence development: an examination of conceptual and policy issues |
| Q37862763 | Coverage with evidence development: the Ontario experience |
| Q56994721 | Delivering affordable cancer care in high-income countries |
| Q36523408 | Demonstrating the value of biologics: a call to action. |
| Q38237573 | Development of coverage with evidence development for medical technologies in Switzerland from 1996 to 2012. |
| Q34974213 | Do economic evaluations of targeted therapy provide support for decision makers? |
| Q84460916 | Do economic evaluations of targeted therapy provide support for decision makers? |
| Q84065086 | Does the public think it is reasonable to wait for more evidence before funding innovative health technologies? The case of PET scanning in Ontario |
| Q50706161 | Dynamics of device innovation: implications for assessing value. |
| Q37677775 | Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems |
| Q34137236 | Generating evidence for comparative effectiveness research using more pragmatic randomized controlled trials. |
| Q28714398 | Health reforms as examples of multilevel interventions in cancer care |
| Q30636005 | Health technology assessment in Switzerland: a descriptive analysis of "Coverage with Evidence Development" decisions from 1996 to 2013. |
| Q44232844 | How Best To Engage Patients, Doctors, And Other Stakeholders In Designing Comparative Effectiveness Studies |
| Q34141797 | How Medicare Could Use Comparative Effectiveness Research In Deciding On New Coverage And Reimbursement |
| Q30913092 | How can we support the use of systematic reviews in policymaking? |
| Q42872626 | Hyperbaric oxygen therapy for post-concussion syndrome: contradictory conclusions from a study mischaracterized as sham-controlled |
| Q24289148 | Impact of alternative medical device approval processes on costs and health |
| Q34500953 | Impact of dedicated brain PET on intended patient management in participants of the national oncologic PET Registry |
| Q91687079 | Innovation as a value in healthcare priority-setting: the UK experience |
| Q34608654 | Insurance coverage policies for personalized medicine |
| Q49387694 | Insurance for broad genomic tests in oncology |
| Q50147449 | Integrating molecular medicine into the US health-care system: opportunities, barriers, and policy challenges |
| Q36869758 | Intended versus inferred management after PET for cancer restaging: analysis of Medicare claims linked to a coverage with evidence development registry |
| Q28292892 | International comparison of comparative effectiveness research in five jurisdictions: insights for the US |
| Q81581696 | Key principles for the improved conduct of health technology assessments for resource allocation decisions |
| Q55395400 | Making a decision to wait for more evidence: when the National Institute for Health and Clinical Excellence recommends a technology only in the context of research. |
| Q85064219 | Medicare's Coverage With Evidence Development: A Policy-Making Tool in Evolution |
| Q35189884 | Medicare's policy on carotid stents limited use to hospitals meeting quality guidelines yet did not hurt disadvantaged |
| Q53236582 | Methodology of constructive technology assessment in health care. |
| Q81923873 | NICE's 2008 Methods Guide: sensible consolidation or opportunities missed? |
| Q38384271 | One million haemopoietic stem-cell transplants: a retrospective observational study |
| Q38093054 | Optimal global value of information trials: better aligning manufacturer and decision maker interests and enabling feasible risk sharing |
| Q44871497 | Orphan drugs for rare diseases: is it time to revisit their special market access status? |
| Q55054232 | Overhauling the reimbursement system for molecular diagnostics. |
| Q36136786 | Personalized medicine and genomics: challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research priorities. |
| Q37556659 | Perspectives on the National Institute for Health and Clinical Excellence's recommendations to use health technologies only in research |
| Q38510741 | Pharmacogenomic and pharmacogenetic-guided therapy as a tool in precision medicine: current state and factors impacting acceptance by stakeholders. |
| Q33721099 | Pharmacogenomics, evidence, and the role of payers |
| Q37058798 | Progress toward personalized medicine for glaucoma |
| Q89474105 | Randomized Trials of Proton Therapy: Why They Are at Risk, Proposed Solutions, and Implications for Evaluating Advanced Technologies to Diagnose and Treat Cancer |
| Q33633396 | Reference pricing with evidence development: a way forward for proton therapy |
| Q37698958 | Relative efficacy of drugs: an emerging issue between regulatory agencies and third-party payers |
| Q36587540 | Say what? |
| Q37103619 | The National Emphysema Treatment Trial (NETT): a study in agency collaboration |
| Q40027009 | The impact of positron emission tomography (PET) on expected management during cancer treatment: findings of the National Oncologic PET Registry |
| Q42735772 | The new medical technologies and the organizations of medical science and treatment |
| Q36825747 | Toward clinical genomics in everyday medicine: perspectives and recommendations |
| Q53751225 | Use of economic evaluation in decision making: evidence and recommendations for improvement. |
| Q37787227 | Using comparative effectiveness research to inform policy and practice in the UK HHS: past, present and future |
| Q82324070 | Web-based toolkit to facilitate European collaboration on evidence generation on promising health technologies |
Search more.